居裡 CRIS 深 滬
已收盤 09-19 16:00:00 美东时间
1.70
-0.020
-1.16%
華盛通- 最 高1.7574
- 今 開1.7537
- 成交量 5.95万股
- 最 低 1.66
- 昨 收 1.72
- 總市值 1778.59万
- 52周最高 5.54
- 市盈率 靜 --
- 換手率 0.57%
- 52周最低 1.02
- 委 比 75.30%
- 總股本 1046.23万
- 歷史最高 565.00
- 量 比 0.77
- 振 幅 5.66%
- 歷史最低 1.02
- 每 手 1
- 風險率 1.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aptevo Expands Anti-Cancer Pipeline With Patents For APVO452, APVO451; Acute Myeloid Leukemia Candidate Mipletamig Shows Strong Clinical Validation
New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEXTM design to target prostate and multiple solid tumor cancers by simultaneously engaging tumor antigens, T cells, and immunosuppressive
09-04 20:50
Comstock Announces the Purchase of All Equipment for Industry Scale Facility
Comstock Inc. has placed orders and paid $5.1 million in deposits for $10.5 million in equipment to build a 100,000-ton per year solar panel recycling facility in Nevada, with additional spending planned for storage and upgrades. The facility aims to achieve zero-landfill certification and is scheduled to commission in Q1 2026, with operations set to begin in Q2 2026. The company also intends to expand its recycling capabilities globally and deve...
08-25 20:15
Curis Appeals Nasdaq Delisting Notice After Non-Compliance
An update from Curis ( ($CRIS) ) is now available. On February 21, 2025, Curis,...
08-23 04:34
投资者正获利了结？ARK创新ETF(ARKK.US)遭大规模赎回 “木头姐”伍德仍在逢低买入更多股票
由“木头姐”伍德管理的ARK创新ETF今年以来表现亮眼，但近期资金流向显示投资者可能在获利了结
08-20 06:00
Aptevo Unveils APVO442 Precision CD3 Bispecific For Prostate Cancer, Advancing Solid Tumor Strategy With CRIS-7 Platform
Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.Engineered for precision T-cell activation in prostate cancer; part of Aptevo's growing CRIS-7-derived CD3
08-13 20:14
Curis Files Prospectus Supplement for Stock Offering
Curis ( ($CRIS) ) has provided an update. On August 8, 2025, Curis, Inc. announ...
08-09 05:48
Curis Q2 EPS $(0.68) Beats $(1.36) Estimate, Sales $2.75M Beat $2.64M Estimate
Curis (NASDAQ:CRIS) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(1.36) by 50 percent. This is a 66.5 percent increase over losses of $(2.03) per share from the same period
08-05 20:02
Curis Provides Second Quarter 2025 Business Update
Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass., Aug. 5, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the develop...
08-05 20:00
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
A Peek at Curis's Future Earnings
Curis (NASDAQ:CRIS) is gearing up to announce its quarterly earnings on Tuesday...
08-05 05:04
